重组组织型纤溶酶原激活剂静脉溶栓对急性脑梗死的治疗作用研究

Therapeutic Effect of Recombinant Tissue Plasminogen Activator Intravenous Thrombolysis on Acute Cerebral Infarction

目的研究急性脑梗死采用重组组织型纤溶酶原激活剂静脉溶栓治疗的效果。方法选择2018年6月—2019年6月期间该院收治的82例急性脑梗死患者,使用奇偶法将患者平均分为对照组与观察组,每组41例,对照组接受常规治疗,观察组接受重组组织型纤溶酶原激活剂静脉溶栓治疗,比较两组急性脑梗死患者的临床治疗效果。结果观察组治疗当天(40.70±1.26)分、治疗1周后(30.85±4.27)分和治疗2周后(21.07±5.69)分患者的NIHSS量表评分均小于对照组,差异有统计学意义(t=21.060、5.883、8.842,P=0.000、0.000、0.000<0.05)。观察组血浆粘度(1.73±0.06)mPa·s、全血高切粘度(5.25±0.27)mPa·s、全血低切粘度(10.17±3.05)mPa·s、纤维蛋白原(3.71±0.65)g/L治疗后均优于对照组,差异有统计学意义(t=10.655、11.775、1.999、4.712,P=0.000、0.000、0.0490、0.000<0.05)。观察组的颅内出血发生率(2.44%)和病死率(0.00%)小于对照组(26.83%,9.76%),差异有统计学意义(χ^2=9.762、4.205,P=0.002、0.040<0.05)。结论急性脑梗死采用重组组织型纤溶酶原激活剂静脉溶栓治疗效果显著,可以更好的改善患者的治疗成效,具有临床使用与推广价值。

Objective To study the effect of intravenous thrombolysis with recombinant tissue plasminogen activator on acute cerebral infarction.Methods From June 2018 to June 2019,82 patients with acute cerebral infarction admitted to our hospital were divided into the control group and the observation group using the odd-even method.The control group received conventional treatment and the observation group received intravenous thrombolytic therapy with recombinant tissue-type plasminogen activator,and compared the clinical therapeutic effects of two groups of patients with acute cerebral infarction.Results The observation group’s NIHSS scale scores on the day of treatment(40.70±1.26)points,1 week after treatment(30.85±4.27)points and 2 weeks after treatment(21.07±5.69)points were lower than those in the control group,the difference was statistically significant(t=21.060,5.883,8.842,P=0.000,0.000,0.000<0.05).Observation group plasma viscosity(1.73±0.06)mPa·s,whole blood high-cut viscosity(5.25±0.27)mPa·s,whole blood low-cut viscosity(10.17±3.05)mPa·s,fibrinogen(3.71±0.65)g/L was better than the control group after treatment,the difference was statistically significant(t=10.655,11.775,1.999,4.712,P=0.000,0.000,0.0490,0.000<0.05).The incidence of intracranial hemorrhage(2.44%)and mortality(0.00%)in the observation group were less than those in the control group(26.83%,9.76%),the difference was statistically significant(χ^2=9.762,4.205,P=0.002,0.040<0.05).Conclusion The treatment of acute cerebral infarction with recombinant tissue-type plasminogen activator intravenous thrombolysis has a significant effect,which can better improve the treatment effect of patients,with clinical use and promotion value.